Nitresan (Nitrendipine)

Nitresan, a calcium channel blocker, is indicated for conditions involving elevated vascular resistance.

• Hypertension: reduces systolic and diastolic blood pressure, helping patients achieve target levels.

• Nitrendipine blocks L‑type calcium channels on vascular smooth‑muscle cells, decreasing calcium entry that is required for contraction. This inhibition leads to relaxation of arterial smooth muscle, vasodilation, lowered peripheral vascular resistance, and ultimately a reduction in systemic blood pressure.

Nitrendipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring after dose initiation.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially on standing.
• Tachycardia: increased heart rate.
• Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Myocardial infarction: rare occurrence of heart attack.
• Cardiac arrhythmias: abnormal heart rhythms, including ventricular ectopy.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, angioedema, or anaphylaxis.
• Neutropenia: low white‑blood‑cell count increasing infection risk.

When prescribing Nitresan, clinicians should consider several precautionary measures to ensure safe use.

• Assess baseline blood pressure: confirm hypertension diagnosis before initiating therapy.
• Monitor for orthostatic hypotension: advise patients to rise slowly from sitting or lying positions.
• Evaluate cardiac function: use cautiously in patients with existing heart failure.
• Check liver function: adjust or avoid use in moderate to severe hepatic impairment.
• Avoid use in severe aortic stenosis: risk of profound hypotension.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Nitrendipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension.
• Co‑administration with other antihypertensives (e.g., beta‑blockers, ACE inhibitors): can cause excessive blood‑pressure reduction.
• Use with grapefruit juice: enhances absorption leading to heightened adverse effects.

Moderate Interactions (Monitor Closely)

• Combination with diuretics: may augment electrolyte disturbances.
• Concurrent use with other calcium‑channel blockers: may increase risk of cardiac conduction abnormalities.
• Interaction with rifampicin (CYP3A4 inducer): may reduce nitrendipine efficacy.